Home › Funds › ARMISTICE CAPITAL, LLC › FDMT

ARMISTICE CAPITAL, LLC position in FDMT

4D MOLECULAR THERAPEUTICS IN · Health Care

ARMISTICE CAPITAL, LLC reported holding 2,000,000 shares of FDMT (4D MOLECULAR THERAPEUTICS IN) in its Q2 2026 13F filing — a position valued at US$26.6M, representing 0.35% of its reported portfolio and ranking #42 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed FDMT holdings in 8 of the last 8 reported quarters, going back to Q3 2024.

Latest position (Q2 2026)2.00M sh
Reported value held$26.60M
Portfolio Weight0.35%
First reportedQ3 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ARMISTICE CAPITAL, LLC's FDMT position evolved

ARMISTICE CAPITAL, LLC first disclosed a stake in FDMT in Q3 2024 at 336,000 shares (US$3.6M). The position peaked in Q2 2026 at 2,000,000 shares, worth US$26.6M. Across 8 filings, ARMISTICE CAPITAL, LLC increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 2,000,000 shares valued at US$26.6M. Notable position changes include a 265% increase in Q3 2025 (shares fell 14% over the following quarter), a 77% increase in Q4 2025 (shares rose 24% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 336.00K $3.63M New
Q4 2024 300.00K $1.67M Reduce
Q1 2025 300.00K $969.00K Hold
Q2 2025 300.00K $1.11M Hold
Q3 2025 1.10M $9.52M Add
Q4 2025 1.94M $14.52M Add
Q1 2026 2.00M $18.62M Add
Q2 2026 2.00M $26.60M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About FDMT and 13F data

FDMT (4D MOLECULAR THERAPEUTICS IN) is a Health Care company. 35 other funds we track also report a position in FDMT — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$67.2M), Novo Holdings A/S (US$43.2M), BVF INC/IL (US$38.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding FDMT

All FDMT fund holders →

FAQ

How long has ARMISTICE CAPITAL, LLC held FDMT?

ARMISTICE CAPITAL, LLC has disclosed FDMT holdings in 8 of the last 8 reported quarters, going back to Q3 2024.

What is ARMISTICE CAPITAL, LLC's current position in FDMT?

As of Q2 2026, ARMISTICE CAPITAL, LLC holds 2.00M shares of FDMT (4D MOLECULAR THERAPEUTICS IN), valued at $26.60M, representing 0.35% of its reported portfolio and ranking #42.

Has ARMISTICE CAPITAL, LLC been buying or selling FDMT?

In the latest 13F filing (Q2 2026), ARMISTICE CAPITAL, LLC held unchanged its position in FDMT. The position peaked in Q2 2026 at 2.00M shares.

Which other funds hold FDMT?

Other major institutional holders of FDMT include RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, BVF INC/IL, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.